Dyadic International (DYAI) Income from Continuing Operations (2018 - 2026)
Dyadic International (DYAI) posted Income from Continuing Operations of 1947302.0 for Q1 2026, down 35.27% sequentially from 1439537.0 in Q4 2025, and up 3.66% YoY from 1878625.68 in Q1 2025.
Dyadic International (DYAI) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Dyadic International has reported Income from Continuing Operations for 9 years, with the latest figure at 1947302.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 3.66% year-over-year to 1947302.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7223589.0 (down 26.5% YoY) and the FY2025 annual result came in at 25921731.0, down 12.28% from the prior year.
- Income from Continuing Operations declined to 1947302.0 in Q1 2026 per DYAI's latest filing, from 1439537.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 190216.0 in Q3 2024 and troughed at 7431425.0 in Q2 2022.
- A 5-year average of 2496689.24 and a median of 2021190.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations surged 99.8% in 2022, then tumbled 924.01% in 2025.
- Over 5 years, Income from Continuing Operations stood at 2252568.0 in 2022, then grew by 8.03% to 2071798.0 in 2023, then rose by 23.67% to 1581458.0 in 2024, then advanced by 8.97% to 1439537.0 in 2025, then sank by 35.27% to 1947302.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1947302.0, 1439537.0, and 1947836.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | -1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.95 Mn |
| Dec 31, 2025 | -1.44 Mn |
| Sep 30, 2025 | -1.95 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Mar 31, 2025 | -2.02 Mn |
| Dec 31, 2024 | -1.58 Mn |
| Sep 30, 2024 | -190,216.00 |
| Jun 30, 2024 | -1.92 Mn |
| Mar 31, 2024 | -2.06 Mn |
| Dec 31, 2023 | -2.07 Mn |
| Sep 30, 2023 | -1.61 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -2.59 Mn |
| Dec 31, 2022 | -2.25 Mn |
| Sep 30, 2022 | -2.63 Mn |
| Jun 30, 2022 | -7.43 Mn |
| Mar 31, 2022 | -6.68 Mn |
| Dec 31, 2021 | -12.63 Mn |
| Sep 30, 2021 | -15.86 Mn |
| Jun 30, 2021 | -9.83 Mn |